Large holder update, amended
Open the filing on sec.gov
Nurix Therapeutics, Inc. (NRIX)
Nasdaq: NRIX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
The companyfiscal 2025, as filed
Revenue$84.0M+54.0%
Net income-$264M-36.6%
Earnings per share$-3.05-5.9%
Operating cash flow-$249M-44.5%
Cash$247M+124.5%
Debtn/a
Shareholders’ equity$539M+2.2%
Shares, diluted86.7M+29.1%
Return on equity-49.1%
The recordfrom its filings
Filings in 2026100
Newest filingNov 5 · SCHEDULE 13G/A
Annual reportJan 28, 2026
Quarterly reportOct 13, 2026
Next report due10-K by Jan 29
Insider sales, 12 months$5.8M
Insider buys, 12 months$0.00
Patents granted15
Filer categoryLarge accelerated filer
Trailing twelve months to Aug 2026Revenue $702MNet income $295MCash from operations $379Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.